For foreign Emerging Stock Board enterprises, ”*- country of incorporation” indicates stocks without par value or with par value other than NT$10, and ”- country of incorporation” indicates stocks with par value of NT$10 per share.
|
|
| Basic information |
| Chairman |
President |
Spokesperson |
Telephone |
Address |
ESM Registration Date |
| CHENG-HAN WEN |
HUANG-CHI HUNG |
YU-PEI LIAO |
03-3175088 |
6 F., No. 1490, Chunri Rd., Taoyuan Dist.Taoyuan City 33022, Taiwan (R.O.C.) |
2023/09/07 |
| Industrycategory |
Key businesses |
| Biotechnology and Medical Care |
和迅生命科學股份有限公司設立於民國108年6月12日，為再生醫療細胞治療公司，研發團隊中具生技相關領域碩博士級之比重達80％以上，目標在開發新一代治療藥物，以解決現今未被滿足的醫療需求。和迅公司擁有9間GTP等級的細胞製備室(CPU)，在桃園市政府輔導下領有工廠登記，致力於開發臍帶間質幹細胞新藥治療心血管疾病及衍生疾病，本計畫已通過TFDA查廠並進入將臨床試驗階段，也同時將導入一藥多用的開發理念，來提高藥物效益。
和迅公司目前商品及服務項目以細胞治療與再生醫療製劑之委託開發暨製造服務(CMO/CDMO)、檢測技術服務、GTP實驗室建置與品質文件輔導服務、無菌充填服務、實驗室資訊管理系統為主，創造多元的商業模式，擴大企業利基與生產力。
和迅公司的核心價值在於「創新、專業、卓越」，以深厚技術結合創新思維，秉持「研發創造業務收入，業務收入支持研發」的經營理念，實踐創新的新藥開發商業模式，走出生技業新格局，為台灣的細胞治療產業創造出嶄新模式。 |
| Financial data |
| Cash flows statement
| Item
|
|
|
| Amount(NTD, in thousands) |
| Cash flows from operating activities |
|
|
| Cash flows from investing activities |
|
|
| Cash flows from financing activities |
|
|
Consolidated/Individual
balance sheet
|
Current assets |
|
|
| Non-current assets |
|
|
| Total assets |
|
|
| Current liabilities |
|
|
| Non-current liabilities |
|
|
| Total liabilities |
|
|
| Share capital |
|
|
| Capital surplus |
|
|
| Retained earnings |
|
|
| Other equity interest |
|
|
| Treasury shares |
|
|
| Total equity attributable to owners of parent |
|
|
| Non-controlling interests |
|
|
| Total equity |
|
|
| Book Value per share(NT$) |
|
|
Consolidated/Individual
profit and loss
statement |
Operating revenue |
|
|
| Operating costs |
|
|
| Gross profit from operations |
|
|
| Operating expenses |
|
|
| Net other income (expenses) |
|
|
| Net operating income |
|
|
| Non-operating income and expenses |
|
|
| Profit before tax |
|
|
| Tax expense |
|
|
| Profit from continuing operations |
|
|
| Profit from discontinued operations |
|
|
| Profit |
|
|
| Other comprehensive income |
|
|
| Comprehensive income |
|
|
| Basic earnings per share |
|
|
 Auditor's report on latest financial statements： auditor's report：
|
|
Investors may find more detailed information on the company by visiting the Market Observation Post System.。
|
|
The information disclosed here concerning foreign enterprises consists of amounts provided in consolidated financial statements.
|
